Tirzepatide Bests Semaglutide for Patients With Type 2 Diabetes
Medically reviewed by Drugs.com.
By Lori Solomon HealthDay Reporter
THURSDAY, Oct. 5, 2023 -- Tirzepatide is superior to semaglutide for both blood sugar control and weight loss among people with type 2 diabetes, according to research presented at the European Association for the Study of Diabetes Annual Meeting 2023, held from Oct. 2 to 6 in Hamburg, Germany.
Thomas Karagiannis, M.D., Ph.D., from Aristotle University of Thessaloniki in Greece, and colleagues conducted a network meta-analysis to compare the efficacy and safety of tirzepatide to that of subcutaneous semaglutide in people with type 2 diabetes.
Based on 22 randomized controlled trials (18,472 participants), the researchers found that tirzepatide 15 mg was most efficacious in reducing HbA1c versus placebo (mean difference [MD], −2.00 percent), followed by tirzepatide 10 mg (MD, −1.86 percent) and semaglutide 2.0 mg (MD, −1.62 percent). At each of three respective doses, tirzepatide cut HbA1c more than semaglutide. Tirzepatide was more effective than placebo in reducing body weight. Tirzepatide doses of 10 and 15 mg were more effective in lowering body weight than either semaglutide 1.0 or 2.0 mg, while tirzepatide 5 mg was more effective than semaglutide 0.5 and 1.0 mg. All doses of tirzepatide and semaglutide increased the risk for gastrointestinal adverse events versus placebo, with tirzepatide 15 mg yielding the highest risk for nausea (risk ratio [RR], 3.57), vomiting (RR, 4.35), and diarrhea (RR, 2.04).
"In people with type 2 diabetes, tirzepatide 5, 10, and 15 mg were more efficacious in reducing HbA1c compared to semaglutide 0.5, 1.0, and 2.0 mg, respectively," the authors write.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted October 2023
Read this next
BMI Cutoff of 30 for Obesity May Be Too High for Middle-Aged, Older Adults
FRIDAY, May 31, 2024 -- The optimal body mass index (BMI) cutoff point appears to be 27 kg/m2 for detecting obesity in middle-aged and older adults, according to a study presented...
Semaglutide Cuts Risk for Kidney Outcomes, Death in CKD With T2DM
FRIDAY, May 31, 2024 -- For patients with type 2 diabetes and chronic kidney disease, semaglutide reduces the risk for clinically important kidney outcomes and death from...
Weight Navigation Program Boosts Use of Weight Management Treatments
FRIDAY, May 31, 2024 -- A primary care-based weight navigation program (WNP) is feasible and associated with greater use of weight management treatments (WMT) and weight loss...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.